Literature DB >> 21267309

Fetal surgery.

J M Laberge.   

Abstract

Fetal surgery has come of age. For decades experimental fetal surgery proved essential in studying normal fetal physiology and development, and pathophysiology of congenital defects. Clinical fetal surgery started in the 1960s with intrauterine transfusions. In the 1970s, the advent of ultrasonography revolutionized fetal diagnosis and created a therapeutic vacuum. Fetal treatment, medical and surgical, is slowly trying to fill the gap. Most defects detected are best treated after birth, some requiring a modification in the time, mode and place of delivery for optimal obstetrical and neonatal care. Surgical intervention in utero should be considered for malformations that cause progressive damage to the fetus, leading to death or severe morbidity; that can be corrected or palliated in utero with a reasonable expectation of normal postnatal development; that cannot wait to be corrected after birth, even considering pre-term delivery; that are not accompanied by chromosomal or other major anomalies. At present, congenital hydronephrosis is the most common indication for fetal surgery, followed by obstructive hydrocephalus. Congenital diaphragmatic hernia also fulfills the criteria, but its correction poses more problems, and no clinical attempts have been reported so far. In the future many other malformations or diseases may become best treated in utero. The ethical and moral issues are complex and need to be discussed as clinical and experimental progress is made.

Entities:  

Year:  1986        PMID: 21267309      PMCID: PMC2328225     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  22 in total

1.  INTRAUTERINE TRANSFUSION OF FOETUS IN HAEMOLYTIC DISEASE.

Authors:  A W LILEY
Journal:  Br Med J       Date:  1963-11-02

2.  Transamniotic fetal feeding. III. The effect of nutrient infusion on fetal growth retardation.

Authors:  A W Flake; R L Villa-Troyer; N S Adzick; M R Harrison
Journal:  J Pediatr Surg       Date:  1986-06       Impact factor: 2.545

3.  Pleural effusion and a partial hydropic state.

Authors:  V Kumar; R Broadbent; N N Finer
Journal:  CMAJ       Date:  1986-04-01       Impact factor: 8.262

4.  Correction of congenital hydronephrosis in utero III. Early mid-trimester ureteral obstruction produces renal dysplasia.

Authors:  P L Glick; M R Harrison; R A Noall; R L Villa
Journal:  J Pediatr Surg       Date:  1983-12       Impact factor: 2.545

5.  Unborn: historical perspective of the fetus as a patient.

Authors:  M R Harrison
Journal:  Pharos Alpha Omega Alpha Honor Med Soc       Date:  1982

6.  Intestinal smooth muscle response to chronic obstruction : possible applications in jejunoileal atresia.

Authors:  R Cloutier
Journal:  J Pediatr Surg       Date:  1975-02       Impact factor: 2.545

7.  Fetal sacrococcygeal teratoma.

Authors:  A W Flake; M R Harrison; N S Adzick; J M Laberge; S L Warsof
Journal:  J Pediatr Surg       Date:  1986-07       Impact factor: 2.545

8.  Correction of congenital hydrocephalus in utero II: Efficacy of in utero shunting.

Authors:  P L Glick; M R Harrison; M Halks-Miller; N S Adzick; D K Nakayama; J H Anderson; T G Nyland; R Villa; M S Edwards
Journal:  J Pediatr Surg       Date:  1984-12       Impact factor: 2.545

9.  Correction of congenital hydronephrosis in utero IV: in utero decompression prevents renal dysplasia.

Authors:  P L Glick; M R Harrison; N S Adzick; R A Noall; R L Villa
Journal:  J Pediatr Surg       Date:  1984-12       Impact factor: 2.545

10.  Experimental pulmonary hypoplasia and oligohydramnios: relative contributions of lung fluid and fetal breathing movements.

Authors:  N S Adzick; M R Harrison; P L Glick; R L Villa; W Finkbeiner
Journal:  J Pediatr Surg       Date:  1984-12       Impact factor: 2.545

View more
  1 in total

1.  Fetal tracheal occlusion for the treatment of congenital diaphragmatic hernia.

Authors:  Jean-Martin Laberge; Hélène Flageole
Journal:  World J Surg       Date:  2007-05-18       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.